CA2449284C - Alpha-fetoprotein peptides and uses thereof - Google Patents

Alpha-fetoprotein peptides and uses thereof Download PDF

Info

Publication number
CA2449284C
CA2449284C CA2449284A CA2449284A CA2449284C CA 2449284 C CA2449284 C CA 2449284C CA 2449284 A CA2449284 A CA 2449284A CA 2449284 A CA2449284 A CA 2449284A CA 2449284 C CA2449284 C CA 2449284C
Authority
CA
Canada
Prior art keywords
peptide
seq
peptides
tamoxifen
estrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2449284A
Other languages
English (en)
French (fr)
Other versions
CA2449284A1 (en
Inventor
Thomas T. Andersen
James A. Bennett
Herbert I. Jacobson
Fassil B. Mesfin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albany Medical Center Hospital
Original Assignee
Albany Medical Center Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albany Medical Center Hospital filed Critical Albany Medical Center Hospital
Publication of CA2449284A1 publication Critical patent/CA2449284A1/en
Application granted granted Critical
Publication of CA2449284C publication Critical patent/CA2449284C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2449284A 2001-06-02 2001-06-02 Alpha-fetoprotein peptides and uses thereof Expired - Fee Related CA2449284C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/017748 WO2003007978A1 (en) 2001-06-02 2001-06-02 Alpha-fetoprotein peptides and uses thereof

Publications (2)

Publication Number Publication Date
CA2449284A1 CA2449284A1 (en) 2003-01-30
CA2449284C true CA2449284C (en) 2012-08-21

Family

ID=21742615

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2449284A Expired - Fee Related CA2449284C (en) 2001-06-02 2001-06-02 Alpha-fetoprotein peptides and uses thereof

Country Status (7)

Country Link
EP (1) EP1401467B3 (enExample)
JP (1) JP5073154B2 (enExample)
AT (1) ATE494301T1 (enExample)
AU (1) AU2001268133C1 (enExample)
CA (1) CA2449284C (enExample)
DE (1) DE60143818D1 (enExample)
WO (1) WO2003007978A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044041A2 (en) * 2001-11-20 2003-05-30 Clf Medical Technology Acceleration Program, Inc. Alpha-fetoprotein peptides and uses for imaging
EP1448593B1 (en) * 2001-11-20 2012-01-11 Albany Medical College Alpha-fetoprotein peptides and uses thereof
US7943577B2 (en) 2001-11-20 2011-05-17 Albany Medical College Alpha-fetoprotein peptides and uses thereof
FI118263B (fi) * 2002-10-09 2007-09-14 Timo Kalevi Korpela Kaspaasiaktiivisuutta säätelevät peptidit
WO2005044982A2 (en) 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20110257096A1 (en) * 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US20060111289A1 (en) * 2004-09-09 2006-05-25 Serometrix, Llc, Compositions and methods of using Alpha-fetoprotein growth inhibitory peptides
EA008926B1 (ru) * 2004-12-14 2007-08-31 Товарищество С Ограниченной Ответственностью "Реал Мед Компани" Способ коррекции иммунного состояния организма при анемии
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
CA3221395A1 (en) 2021-06-10 2022-12-15 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674842A (en) * 1994-10-26 1997-10-07 Health Research, Incorporated Growth inhibitory peptide

Also Published As

Publication number Publication date
EP1401467A4 (en) 2005-07-20
AU2001268133C1 (en) 2011-07-07
DE60143818D1 (de) 2011-02-17
ATE494301T1 (de) 2011-01-15
EP1401467B1 (en) 2011-01-05
EP1401467B3 (en) 2014-02-26
AU2001268133B2 (en) 2008-05-15
JP5073154B2 (ja) 2012-11-14
EP1401467A1 (en) 2004-03-31
CA2449284A1 (en) 2003-01-30
JP2004536128A (ja) 2004-12-02
WO2003007978A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
AU2001268133C1 (en) Alpha-fetoprotein peptides and uses thereof
US6818741B2 (en) Alpha-fetoprotein peptides and uses therof
JP4654284B2 (ja) メタスチン誘導体およびその用途
AU2001268133A1 (en) Alpha-fetoprotein peptides and uses thereof
US20090043073A1 (en) Alpha-fetoprotein peptides and uses for imaging
SK17632000A3 (sk) Peptidové antiangiogénne liečivá
AU2016349358B2 (en) Peptides and methods of treating endometriosis using the same
CZ20023517A3 (cs) Peptid modulující trombopoetinový receptor
US20220251140A1 (en) Dpep-1 binding agents and methods of use
US20180273585A1 (en) Medical Use
US6465614B1 (en) High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US7122522B2 (en) Alpha-fetoprotein peptides and uses thereof
US7132400B2 (en) Alpha-fetoprotein peptides and uses thereof
US20110269692A1 (en) Alpha-fetoprotein peptides and uses thereof
US10167326B2 (en) Alpha-fetoprotein “ring and tail” peptides

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180604